<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12189">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509067</url>
  </required_header>
  <id_info>
    <org_study_id>R34MH077849</org_study_id>
    <secondary_id>R34MH077849</secondary_id>
    <secondary_id>DATR A5-ETBD</secondary_id>
    <nct_id>NCT00509067</nct_id>
  </id_info>
  <brief_title>Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia</brief_title>
  <acronym>STAR-1</acronym>
  <official_title>Interventions to Test the Alpha7 Nicotinic Receptor Model in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington D.C. Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of galantamine and CDP-choline in improving
      symptoms associated with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is a life-long brain disorder affecting approximately 1 percent of Americans
      each year. Schizophrenia can be extremely disabling, causing people to hear voices,
      experience paranoia or hallucinations, believe that others are controlling their thoughts,
      and even fail at maintaining a job or caring for themselves. Current medications help to
      relieve most of these negative symptoms, but not all. Many people with schizophrenia still
      suffer from low energy levels, an inability to concentrate, and memory loss. Galantamine is
      a medication that is used to improve memory and energy levels in people with Alzheimer's
      disease, and CDP-choline is a nutritional supplement. The purpose of this study is to
      evaluate the effectiveness of adding galantamine and CDP-choline to a stable anti-psychotic
      medication regimen of risperidone as a way of improving symptoms in adults with
      schizophrenia.

      Participants in this double-blind study will attend an initial screening during which they
      will undergo a physical exam, an electrocardiogram, and blood and urine collection.
      Participants will then be randomly assigned to receive galantamine and CDP-choline or a
      placebo treatment for 16 weeks. Participants assigned to the treatment group will take 500
      mg of CDP-choline daily for the first 3 days, 1,000 mg daily for the next 4 days, and 2,000
      mg daily for the following 15 weeks. Participants assigned to the treatment group will also
      take 8 mg of galantamine daily for the first week, 16 mg daily for the next week, and 24 mg
      daily for the following 14 weeks. Participants assigned to the control group will take two
      types of placebo pills every day for 16 weeks. All participants will continue to take their
      regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
      throughout the trial in addition to their assigned treatment. Staff members will meet with
      participants during the first week of the study and every 4 weeks afterward until study
      completion. During these meetings, participants will identify any side effects, report
      nicotine intake, breathe into a machine that measures the amount of nicotine in the body,
      and complete written and computerized tasks on concentration and memory. Each meeting may
      last up to 3 hours. On the last week of the study, blood and urine samples will be collected
      and an electrocardiogram will be administered. Results from this study will be used to
      evaluate whether CDP-choline and galantamine improve schizophrenia symptoms.

      CDP-choline and matching placebos were purchased from LifeLink Corporation. Galantamine and
      matching placebos were prepared and donated by Ortho McNeil Janssen Scientific Affairs LLC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Measured at Baseline and Weeks 4, 8, 12, and 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>The score for each subject was the sum of the ratings for five items on the negative-symptom subscale of the PANSS: 1) blunted affect, 2) emotional withdrawal, 3) poor rapport, 4) passive/apathetic social withdrawal, and 5) lack of spontaneity and flow of conversation. Each item (symptom) is rated on a scale from 1 = absence of negative symptom to 7 = extreme negative symptom. The sum of the ratings for the five items range from 5 to 35, with higher scores indicating more severe symptoms. The primary outcome measure is the mean of the sum of these ratings across subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression</measure>
    <time_frame>Measured at Baseline and Weeks 4, 8, 12, and 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Measures (MATRICS: Attention, Memory, Processing Speed)</measure>
    <time_frame>Measured at Baseline and Weeks 8 and 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nicotine Use</measure>
    <time_frame>Measured at Baseline and Weeks 4, 8, 12, and 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>Measured at pre- and post-intervention</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to receive galantamine and CDP-choline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants assigned to receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galantamine</intervention_name>
    <description>Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Razadyne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDP-choline</intervention_name>
    <description>CDP-choline will serve as the dietary source of choline. CDP-choline will be titrated to 2000 mg/day over 1 week. Subjects will receive 500 mg/day for 3 days; Thereafter, the dose of CDP-choline will be increased to 1,000 mg/day in two divided doses for 4 days. At the beginning of Week 2, participants will receive the maximum fixed dose of 2000 mg/day in two divided doses, which will be held constant through the end of Week 16.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The schedule of dose titration of placebo galantamine and placebo CDP-choline will follow the schedule of active medication condition using matching placebos for each agent.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole</intervention_name>
    <description>All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV criteria for schizophrenia or schizoaffective disorder

          -  Eligible for care within the Veterans Affairs Medical system

          -  Taking risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole (oral or
             injection)

        Exclusion Criteria:

          -  Significant liver, kidney, lung, endocrine, active peptic ulcer, or cardiovascular
             disease

          -  Seizure disorder and/or head injury

          -  Substance use or abuse within 3 months of study entry

          -  Pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen I. Deutsch, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Veterans Affairs Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Veterans Affairs Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://dx.doi.org/10.1016/j.schres.2013.05.023</url>
    <description>Link for publication of study results</description>
  </link>
  <reference>
    <citation>Deutsch SI, Schwartz BL, Schooler NR, Rosse RB, Mastropaolo J, Gaskins B. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy. Clin Neuropharmacol. 2008 Jan-Feb;31(1):34-9. doi: 10.1097/wnf.0b013e31806462ba.</citation>
    <PMID>18303489</PMID>
  </reference>
  <reference>
    <citation>Deutsch SI, Rosse RB, Schwartz BL, Schooler NR, Gaskins BL, Long KD, Mastropaolo J. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy. Eur Neuropsychopharmacol. 2008 Feb;18(2):147-51. Epub 2007 Jul 26.</citation>
    <PMID>17656074</PMID>
  </reference>
  <reference>
    <citation>Martin LF, Freedman R. Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol. 2007;78:225-46. Review.</citation>
    <PMID>17349863</PMID>
  </reference>
  <reference>
    <citation>Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006 Jun;63(6):630-8.</citation>
    <PMID>16754836</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 10, 2014</lastchanged_date>
  <firstreceived_date>July 30, 2007</firstreceived_date>
  <firstreceived_results_date>July 1, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Mental Health (NIMH)</investigator_affiliation>
    <investigator_full_name>Stephen I. Deutsch</investigator_full_name>
    <investigator_title>Professor and Chair, Dept. of Psychiatry &amp; Behavioral Sciences, Eastern Virginia Medical School</investigator_title>
  </responsible_party>
  <keyword>Schizoaffective Disorder</keyword>
  <keyword>Acetylcholine</keyword>
  <keyword>Nicotinic Receptors</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Galantamine</keyword>
  <keyword>negative symptoms</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Choline</mesh_term>
    <mesh_term>Cytidine Diphosphate Choline</mesh_term>
    <mesh_term>Galantamine</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Quetiapine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Galantamine/CDP Choline</title>
          <description>Participants assigned to receive galantamine and CDP-choline</description>
        </group>
        <group group_id="P2">
          <title>Placebos for Galantamine/CDP Choline</title>
          <description>Participants assigned to receive placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Galantamine/CDP Choline</title>
          <description>Participants assigned to receive galantamine and CDP-choline</description>
        </group>
        <group group_id="B2">
          <title>Placebos for Galantamine/CDP Choline</title>
          <description>Participants assigned to receive placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="41"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="54.37" spread="8.50"/>
                <measurement group_id="B2" value="52.38" spread="11.04"/>
                <measurement group_id="B3" value="53.28" spread="9.94"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS)</title>
        <description>The score for each subject was the sum of the ratings for five items on the negative-symptom subscale of the PANSS: 1) blunted affect, 2) emotional withdrawal, 3) poor rapport, 4) passive/apathetic social withdrawal, and 5) lack of spontaneity and flow of conversation. Each item (symptom) is rated on a scale from 1 = absence of negative symptom to 7 = extreme negative symptom. The sum of the ratings for the five items range from 5 to 35, with higher scores indicating more severe symptoms. The primary outcome measure is the mean of the sum of these ratings across subjects.</description>
        <time_frame>Measured at Baseline and Weeks 4, 8, 12, and 16</time_frame>
        <safety_issue>No</safety_issue>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Galantamine/CDP Choline</title>
            <description>Participants assigned to receive galantamine and CDP-choline</description>
          </group>
          <group group_id="O2">
            <title>Placebos for Galantamine/CDP Choline</title>
            <description>Participants assigned to receive placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS)</title>
            <description>The score for each subject was the sum of the ratings for five items on the negative-symptom subscale of the PANSS: 1) blunted affect, 2) emotional withdrawal, 3) poor rapport, 4) passive/apathetic social withdrawal, and 5) lack of spontaneity and flow of conversation. Each item (symptom) is rated on a scale from 1 = absence of negative symptom to 7 = extreme negative symptom. The sum of the ratings for the five items range from 5 to 35, with higher scores indicating more severe symptoms. The primary outcome measure is the mean of the sum of these ratings across subjects.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17.63" spread="3.48"/>
                  <measurement group_id="O2" value="18.29" spread="4.52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17.06" spread="5.6"/>
                  <measurement group_id="O2" value="17.08" spread="5.64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.93" spread="5.09"/>
                  <measurement group_id="O2" value="17.26" spread="5.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.93" spread="5.2"/>
                  <measurement group_id="O2" value="17.32" spread="5.21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 16</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.93" spread="5.2"/>
                  <measurement group_id="O2" value="16.05" spread="5.97"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression</title>
        <time_frame>Measured at Baseline and Weeks 4, 8, 12, and 16</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Measures (MATRICS: Attention, Memory, Processing Speed)</title>
        <time_frame>Measured at Baseline and Weeks 8 and 16</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nicotine Use</title>
        <time_frame>Measured at Baseline and Weeks 4, 8, 12, and 16</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Electrocardiogram</title>
        <time_frame>Measured at pre- and post-intervention</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected weekly over 16 weeks for each participant.</time_frame>
      <desc>Table presents adverse events by group that were at least moderate at any time point.
All AEs were assessed (systematic assessment) on a scale from 1 = absent to 4 = severe.</desc>
      <group_list>
        <group group_id="E1">
          <title>Galantamine/CDP Choline</title>
          <description>Participants assigned to receive galantamine and CDP-choline</description>
        </group>
        <group group_id="E2">
          <title>Placebos for Galantamine/CDP Choline</title>
          <description>Participants assigned to receive placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hospitalized for cardiac symptoms</sub_title>
                <description>One placebo participant was hospitalized with cardiac symptoms. This SAE resolved.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Decrease in Appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sleep problem</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Excess Salivation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stephen I. Deutsch</name_or_title>
      <organization>Department of Psychiatry Georgetown University Medical School</organization>
      <phone>757.446.5888</phone>
      <email>DeutscSI@EVMS.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
